Grant Thornton advises Moroccan Laso-Bio SA

Laso-Bio, a leading Moroccan company, has received approval from the Competition Council to acquire the German companies New Garden Pharma and myherbliz, a move set to significantly enhance its market position in the cannabidiol industry.

An interdisciplinary cross-border team from Grant Thornton in Germany, led by partners Stefan Blum (Financial), Dr. Stephane Müller (Commercial), Dr. Achim Kestler (Tax), and Dr. Mathias Reif (Legal), and in Morocco by partner Moulay El Amine El Hammoumi Idrissi (Legal), provided comprehensive advisory services. The team conducted Financial Due Diligence, Commercial Due Diligence, Tax Due Diligence, and Legal Due Diligence, ensuring a thorough evaluation and mitigation of risks associated with the transaction, both from a German and a Moroccan point of view.

This acquisition marks a significant step in Laso-Bio's growth strategy, expanding its footprint in the European market. With the integration of New Garden Pharma and myherbliz, Laso-Bio is poised to leverage synergies, enhance its product offerings, and accelerate its growth in the competitive cannabidiol and cannabis industry.

New Garden Pharma and myherbliz are well-established players in the European Cannabidiol market. myherbliz specialises in the development and production of high-quality herbal products, including oils, topicals, and wellness items. Known for its innovative approach and commitment to quality, myherbliz has built a strong reputation and loyal customer base across Europe. New Garden Pharma complements this with its robust distribution network and expertise in the regulatory landscape, making them strategic acquisitions for Laso-Bio.